Editorial: The 2024 Revision of the Declaration of Helsinki and its Continued Role as a Code of Ethics to Guide Medical Research

On October 19, 2024, the World Medical Association (WMA) announced the adoption of the 2024 Revision of the Declaration of Helsinki, a statement document of ethical principles for research involving humans, human data, and human cells and tissues [1]. The revision process was undertaken over more than two years with international collaboration to enhance the inclusivity of medical research, protect the rights of research study participants, and address contemporary research challenges such as global health emergencies and data privacy [1]. The revised Declaration document updates the previous 2013 Declaration of Helsinki in several ways [1,2]. Table 1 summarizes the fundamental changes and updates to the content of the 2024 Declaration of Helsinki [1].

The WMA was established in 1947 in response to concerns regarding the ethics of medical and research practices during and after World War II [3]. Since 1947, the WMA has provided a platform for developing and maintaining a global consensus on medical ethics [3]. In 1964, the WMA adopted the first Declaration of Helsinki to establish ethical principles for medical research involving humans [3]. However, although the first Declaration document was driven by international laws that include the Nuremberg Code, the Declaration of Helsinki has never been an official legal document, and the WMA has no legal authority or procedures [4]. However, for more than six decades, the Declaration of Helsinki has been the most recognized and influential international code of ethics guiding medical research [4]. Although the Declaration of Helsinki includes unchanged fundamental ethical principles, the document has been revised several times as medical research has progressed [3].

The history of the WMA and the history of research regulation has focused on protecting individual study participants [3,5]. However, similar ethical frameworks that guide medical interventions in clinical practice still need to be developed [5]. The Declaration of Helsinki guides the protection of participants in trials of experimental or new or previously untested interventions [3]. However, for clinical research of lower risk, such as comparative efficacy studies, guidance may be misaligned, as research participants are highly protected but patients in clinical practice may be under-protected [5,6]. Ethical oversight for clinical trials and the patients who participate in clinical trials, as well as regulatory practice, requires consideration of study design, patient risk, and the requirements of participant research consent [5,7].

Several authors have commented on the main revisions to the 2024 Declaration document and the implications of these revisions [1,5,8,9]. An important addition to the Declaration document is guidance on the appreciation of global ethical challenges that require responsible inclusivity in research with appropriate safeguards, particularly for underrepresented and marginalized groups (Table 1) [1,8]. The roles of research Ethics Committees in the approval, monitoring, and implementation of medical research have been highlighted (Table 1) [1,8,9]. The revised Declaration document has developed beyond its traditional focus on individual research participants to emphasize community engagement and global responsibility for ethics, avoid waste, and reduce the ecological impact of the research study (Table 1) [1,9].

Access to patient health data and biobanks has rapidly developed since the 2013 Declaration document, and the roles of machine learning or artificial intelligence (AI) in medical research have begun to be realized [10]. Each year, the number of medical research studies that include the applications of artificial intelligence (AI) in medical research, including studies with patients and patient data, continues to rise [10]. AI is now used in clinical drug development, drug target selection, and patient selection to accelerate clinical trials [11,12]. There are concerns regarding ethical issues, including patient confidentiality and the lack of evidence-based clinical guidelines that require support from clinical trial data using AI [10,13,14]. In September 2020, the CONSORT-A1 extension guidelines were developed with 14 additional reporting items [14]. However, ethical guidance has yet to keep pace with medical research that involves human and AI interactions [14]. There is an increasing need for ethical data governance and improved clarity regarding current and future applications, ethical considerations, and potential risks of AI in medical research (Table 1) [1,13]. The WMA will continue to revise the Declaration of Helsinki document to improve human health through medical research [1,15]. Data-driven research is expected to increase, which means that consent, the rights of study participants, and risk minimization will require ethical guidance [1,15].

Conclusions

The Declaration of Helsinki has provided an international code of ethics to guide medical research for over six decades. The revised Declaration document does not replace the roles of the Institutional Review Board and the local Ethics Committee in reviewing and approving all research study protocols but continues to provide ethical guidance for the individuals who support, review, and conduct medical research.